Intra Dialytic Parenteral Nutrition and Nutritional Gap Nutritional Gap Identified by Indirect Calorimetry
DiaPaNIC
1 other identifier
interventional
20
1 country
1
Brief Summary
Renal failure is a relevant condition as the incidence of patients treated with intermittent dialysis continues to grow each year. One of the strongest predictors of mortality in these patients is Protein-Energy Wasting (PEW). Optimal nutritional support, combined with physical exercise may be able to improve the physical condition objectified as muscle wasting and weakness. Correct nutritional support must aim to supplement the correct combination of protein and caloric needs. Although no other way exist than predicting formula to assess protein need, predicting formula don't seem to capture the individual caloric need of the patients. The gold standard to assess caloric need by measuring Resting Energy Expenditure (REE) is indirect calorimetry. Even when caloric and protein targets are defined, intake remains a challenge because of intake restriction in dietary patterns. This is why intradialytic parenteral nutrition (IDPN) can play an crucial role for closing the nutritional gap. Whether IDPN guided by indirect calorimetric measurements of metabolism can close the gap when oral intake fails, remains an unanswered question.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Oct 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 30, 2022
CompletedFirst Posted
Study publicly available on registry
October 6, 2022
CompletedStudy Start
First participant enrolled
October 4, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
August 31, 2024
CompletedDecember 6, 2023
November 1, 2023
11 months
August 30, 2022
December 5, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Caloric adequacy
caloric intake (kcal/day) and caloric need (kcal/day) (see secondary outcomes) will be combined to report caloric adequacy according to this equation: \[sum of percentage of caloric intake/caloric need\]/total of evaluable nutrition days (%)
Pre-dialysis
Secondary Outcomes (11)
Protein adequacy
Pre-dialysis
Fat Mass (FM)
20-30 minutes after dialysis
Fat Free Mass (FFM)
20-30 minutes after dialysis
Phase angle
20-30 minutes after dialysis
Body weight
before and after hemodialysis
- +6 more secondary outcomes
Other Outcomes (6)
Descriptive outcomes
pre-dialysis
Dialysis type
During dialysis
Delta REE between predicting formula and indirect calorimetry
Pre-dialysis
- +3 more other outcomes
Study Arms (1)
Assessments
EXPERIMENTALIn this single-arm trial, each participant undergoes the following measurements/assessments: Physical: Body weight (before and after dialysis), length Biophysical: NRS2002, GLIM, Bio-electrical Impedance Analysis Metabolic: Indirect Calorimetry Nutritional: dietary anamnesis, 3-days nutritional diary
Interventions
Indirect Calorimetry (Q-NRG Metabolic Monitor, COSMED) is performed to determine the Resting Energy Expenditure before hemodialysis.
Bio-electrical Impedance Analysis (BIA101/BIVA, Akern) is used to analyse the body composition (Fat Mass, Fat Free Mass, Phase Angle).
The Nutritional assessments consist of a dietary anamnesis and a 3-day nutritional diary to determine the nutritional (caloric and protein) intake of the participants.
Eligibility Criteria
You may qualify if:
- Patient on intermittent hemodialysis
- Protein-Energy Wasting defined as 5% within 3 months or 10% within 6 months (not due to water loss, established at the discretion of the treating physician)
You may not qualify if:
- Pregnancy
- Contra-indications for the use of indirect calorimetry as stated by the AARC (oxygen therapy for COPD,...)
- Metabolic diseases
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Universitair Ziekenhuis Brussellead
- Baxter Healthcare Corporationcollaborator
Study Sites (1)
Universitair Ziekenhuis Brussel
Jette, Brussels Capital, 1090, Belgium
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Elisabeth De Waele, MD, PhD
Universitair Ziekenhuis Brussel
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 30, 2022
First Posted
October 6, 2022
Study Start
October 4, 2023
Primary Completion
August 31, 2024
Study Completion
August 31, 2024
Last Updated
December 6, 2023
Record last verified: 2023-11
Data Sharing
- IPD Sharing
- Will not share